Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.76 |
| ▸ | CA2 | P00918 | 6/20 | 0.76 |
| ▸ | CA9 | Q16790 | 6/20 | 0.76 |
| ▸ | CA12 | O43570 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22670497 | 0.86 | MAPT (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL2223232 | 0.84 | MAPT (0.66) | CA1CA2CA9CA12MAPT | |
| SCHEMBL8428070 | 0.82 | CA1 (0.54) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4108427 | 0.82 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL2203669 | 0.81 | MAPT (0.77) | CA1CA2CA9CA12MAPT | |
| SCHEMBL118345 | 0.80 | MAPT (0.97) | CA1CA2CA9CA12MAPT | |
| SCHEMBL7989098 | 0.80 | CA1 (0.57) | CA1CA2CA9CA12MAPT | |
| Hydrochloric Acid SCHEMBL8625650 | 0.79 | MAPT (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL3410994 | 0.79 | MAPT (0.55) | CA1CA2CA9CA12MAPT | |
| SCHEMBL6953270 | 0.79 | ALDH1A1 (0.55) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348694-A1 | SHELF LIFE- AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348694-A1 | SHELF LIFE- AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348694-A1 | SHELF LIFE- AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2021105038-A1 | SHELF LIFE- AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-9005670-B2 | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2011085039-A2 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-0743304-B1 | 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones | MERCK PATENT GMBH (DE) | 2003-03-26 | — | — | EP | disclosed |
| CN-1066138-C | 4-(arylaminomethylene)-2,4-dihydro-3-pyrazolones | MERCK PATENT GMBH (DE) | 2001-05-23 | — | — | CN | disclosed |
| CN-1141291-A | 4-(Arylaminomethylene)-2,4-dihydro-3-pyrazolones | MERCK PATENT GMBH (DE) | 1997-01-29 | — | — | CN | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | EP300, HDAC1, KAT2A | CA1 2815/4885CA2 2625/4885CA9 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.